James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 21,116 shares at $14.65 ($309K) on 2025-09-30, disclosed to the SEC on 2025-10-02.
Open-market sale of $309k AMLX by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.65 | 10,558 | $155K | 50.0% |
| 2 | $14.65 | 10,558 | $155K | 50.0% |
| Total | $14.65 avg | 21,116 | $309K | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-04-02 | $38K | — | Filing → |